Download PDF
Semin Liver Dis 2003; 23(2): 183-194
DOI: 10.1055/s-2003-39949
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Hepatotoxicity Associated with Antiretroviral Therapy Containing HIV-1 Protease Inhibitors

Mark S. Sulkowski
  • Assistant Professor of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland
Further Information

Publication History

Publication Date:
11 June 2003 (online)

    Permissions and Reprints

ABSTRACT

Human immunodeficiency virus 1 (HIV-1) protease inhibitors are important components of highly active antiretroviral therapy and have had a profound impact on the natural history of HIV and AIDS. However, in the era of highly active antiretroviral therapy (HAART), drug-induced hepatotoxicity or liver injury has emerged as an important potential complication of combination antiretroviral therapy, particularly those regimens containing protease inhibitors (PIs). Liver injury has been associated each of the six PIs currently approved by the U. S. Food and Drug Administration (FDA), most commonly with administration of full dose ritonavir (600 mg bid or 400 mg bid with saquinavir). However, this regimen has been largely replaced by the use of low-dose ritonavir (≤ 200 mg bid) to pharmacologically "boost" other PI, such as lopinavir or indinavir, which has not been associated with an increased risk of hepatotoxicity compared with other PIs. Coinfection with hepatitis C virus (HCV) and B virus (HBV) remains an important risk factor for the development of HAART-associated liver injury. Although studies indicate that coinfected patients can be safely treated with PIs, such patients should be closely monitored. In addition, although unsubstantiated, some experts recommend evaluation or treatment, or both, of underlying chronic viral hepatitis prior to the initiation of antiretroviral therapy. Further research is needed to understand the etiopathogenesis of PI-associated liver injury, particularly among patients with hepatitis B or C infection.

KEYWORDS

HIV - protease inhibitors - hepatotoxicity - HBV - HCV

REFERENCES

  • 1 Palella Jr J F, Delaney K M, Moorman A C. et al . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.  N Engl J Med . 1998;  338 853-860
    CrossrefPubMedGoogle Scholar
  • 2 Lee L M, Karon J M, Selik R, Neal J J, Fleming P L. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997.  JAMA . 2001;  285 1308-1315
    CrossrefPubMedGoogle Scholar
  • 3 Hogg R S, Heath K V, Yip B. et al . Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.  JAMA . 1998;  279 450-454
    CrossrefPubMedGoogle Scholar
  • 4 Carr A, Cooper D A. Adverse effects of antiretroviral therapy.  Lancet . 2000;  356 1423-1430
    CrossrefPubMedGoogle Scholar
  • 5 Fellay J, Boubaker K, Ledergerber B. et al . Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.  Lancet . 2001;  358 1322-1327
    CrossrefPubMedGoogle Scholar
  • 6 Freiman J P, Helfert K E, Hamrell M R, Stein D S. Hepatomegaly with severe steatosis in HIV-seropositive patients.  AIDS . 1993;  7 379-385
    CrossrefPubMedGoogle Scholar
  • 7 Matsuda J, Gohchi K. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir.  Lancet . 1997;  350 364
    PubMedGoogle Scholar
  • 8 Brau N, Leaf H L, Wieczorek R L, Margolis D M. Severe hepatitis in three AIDS patients treated with indinavir.  Lancet . 1997;  349 924-925
    PubMedGoogle Scholar
  • 9 Sulkowski M S, Thomas D L, Chaisson R E, Moore R D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.  JAMA . 2000;  283 74-80
    CrossrefPubMedGoogle Scholar
  • 10 Sulkowski M S, Thomas D L, Mehta S H, Chaisson R E, Moore R D. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.  Hepatology . 2002;  35 182-189
    CrossrefPubMedGoogle Scholar
  • 11 den Brinker M, Wit F W, Wertheim-van Dillen M P. et al . Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.  AIDS . 2000;  14 2895-2902
    CrossrefPubMedGoogle Scholar
  • 12 Wit F W, Weverling G J, Weel J, Jurriaans S, Lange J M. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.  J Infect Dis . 2002;  186 23-31
    CrossrefPubMedGoogle Scholar
  • 13 Saves M, Vandentorren S, Daucourt V. et al . Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA).  AIDS . 1999;  13 F115-F121
    CrossrefPubMedGoogle Scholar
  • 14 Gisolf E H, Dreezen C, Danner S A, Weel J L, Weverling G J. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group.  Clin Infect Dis . 2000;  31 1234-1239
    CrossrefPubMedGoogle Scholar
  • 15 Saves M, Raffi F, Clevenbergh P. et al . Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group.  Antimicrob Agents Chemother . 2000;  44 3451-3455
    CrossrefPubMedGoogle Scholar
  • 16 Nunez M, Lana R, Mendoza J L, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.  J Acquir Immune Defic Syndr . 2001;  27 426-431
    PubMedGoogle Scholar
  • 17 Monforte A A, Bugarini R, Pezzotti P. et al . Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.  J Acquir Immune Defic Syndr . 2001;  28 114-123
    CrossrefPubMedGoogle Scholar
  • 18 Bonfanti P, Landonio S, Ricci E. et al . Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy.  J Acquir Immune Defic Syndr . 2001;  27 316-318
    CrossrefPubMedGoogle Scholar
  • 19 Cooper C L, Parbhakar M A, Angel J B. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus.  Clin Infect Dis . 2002;  34 1259-1263
    CrossrefPubMedGoogle Scholar
  • 20 Aceti A, Pasquazzi C, Zechini B, De Bac C. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection.  J Acquir Immune Defic Syndr . 2002;  29 41-48
    PubMedGoogle Scholar
  • 21 Crixivan(r) (indinavir sulfate) Package Insert. West Point, PA: Merck and Co., Inc. 1999
    Google Scholar
  • 22 Viracept(r) (nelfinavir mesylate) Package Insert. La Jolla, CA: Agouron Pharmaceuticals, Inc.; 2001. 
    Google Scholar
  • 23 Agenerase(r) (amprenavir) Package Insert. Research Triangle Park, NC: GlaxoSmithKline, Inc.; 2002. 
    Google Scholar
  • 24 Norvir(r) (ritonavir capsules) Package Insert. North Chicago, IL: Abbott Laboratories; 2001. 
    Google Scholar
  • 25 Fortavase(r) (saquinavir soft gelatin capsule) Package Insert. Nutley, NJ: Roche Laboratories Inc.; 2002. 
    Google Scholar
  • 26 KaletraTM (lopinavir/ritonavir) Package Insert. North Chicago, IL: Abbott Laboratories 2002
    Google Scholar
  • 27 Flexner C. HIV-protease inhibitors.  N Engl J Med 1998: 338:1281-1292
    Google Scholar
  • 28 Veronese L, Rautaureau J, Sadler B M. et al . Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.  Antimicrob Agents Chemother . 2000;  44 821-826
    CrossrefPubMedGoogle Scholar
  • 29 Moyle G J, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement.  HIV Med . 2001;  2 105-113
    CrossrefPubMedGoogle Scholar
  • 30 Walmsley S, Bernstein B, King M. et al . Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.  N Engl J Med . 2002;  346 2039-2046
    CrossrefPubMedGoogle Scholar
  • 31 Sham H L, Kempf D J, Molla A. et al . ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.  Antimicrob Agents Chemother . 1998;  42 3218-3224
    CrossrefPubMedGoogle Scholar
  • 32 Spengler U, Lichterfeld M, Rockstroh J K. Antiretroviral drug toxicity-a challenge for the hepatologist?.  J Hepatol . 2002;  36 283-294
    CrossrefPubMedGoogle Scholar
  • 33 Miwa L J, Jones J K, Pathiyal A, Hatoum H. Value of epidemiologic studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story.  Arch Intern Med . 1997;  157 2129-2136
    CrossrefPubMedGoogle Scholar
  • 34 AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experieinces Rockville, MD: Division of AIDS. National Institute of Allergy and Infectious Diseases; 1996
  • 35 Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting.  J Hepatol . 1990;  11 272-276
    PubMedGoogle Scholar
  • 36 Zucker S D, Qin X, Rouster S D. et al . Mechanism of indinavir-induced hyperbilirubinemia.  Proc Natl Acad Sci USA . 2001;  98 12671-12676
    CrossrefPubMedGoogle Scholar
  • 37 Arribas J R, Ibanez C, Ruiz-Antoran B. et al . Acute hepatitis in HIV-infected patients during ritonavir treatment.  AIDS . 1998;  12 1722-1724
    PubMedGoogle Scholar
  • 38 Masur Pb H P, Kaplan J E, Holmes K K. Guidelines for preventing opportunistic infections among HIV-infected persons- 2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America.  Ann Intern Med . 2002;  137 435-478
    PubMedGoogle Scholar
  • 39 Sulkowski M S, Thomas D L. Hepatitis C in the HIV infected patient.  Ann Intern Med . 2002;  138 197-207
    PubMedGoogle Scholar
  • 40 Manegold C, Hannoun C, Wywiol A. et al . Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy.  Clin Infect Dis . 2001;  32 144-148
    CrossrefPubMedGoogle Scholar
  • 41 Velasco M, Moran A, Tellez M J. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient (Letter).  N Engl J Med . 1999;  340 1765-1766
    CrossrefPubMedGoogle Scholar
  • 42 Bessesen M, Ives D, Condreay L, Lawrence S, Sherman K E. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.  Clin Infect Dis . 1999;  28 1032-1035
    CrossrefPubMedGoogle Scholar
  • 43 Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine- resistant hepatitis B virus.  N Engl J Med . 2003;  348 177-178
    CrossrefPubMedGoogle Scholar
  • 44 Nelson M, Portsmouth S, Stebbing J. et al . An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.  AIDS . 2003;  17 F7-F10
    CrossrefPubMedGoogle Scholar
  • 45 Pillay D, Cane P A, Ratcliffe D, Atkins M, Cooper D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee.  AIDS . 2000;  14 1111-1116
    PubMedGoogle Scholar
  • 46 Jeffers L J, Coelho-Little M E, Cheinquer H. et al . Procollagen-III peptide and chronic viral C hepatitis.  Am J Gastroenterol . 1995;  90 1437-1440
    PubMedGoogle Scholar
  • 47 Feinman S V, Berris B, Sinclair J C. E antigen and anti-e in HBsAg carriers.  Lancet . 1975;  II 1173-1174
    PubMedGoogle Scholar
  • 48 Vora S, Michon C, Junet C. et al . Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests.  AIDS . 2000;  14 2795-2797
    PubMedGoogle Scholar
  • 49 Vento S, Garofano T, Renzini C. et al . Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy.  AIDS . 1998;  12 116-117
    PubMedGoogle Scholar
  • 50 Riddle T M, Kuhel D G, Woollett L A, Fichtenbaum C J, Hui D Y. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.  J Biol Chem . 2001;  276 37514-37519
    CrossrefPubMedGoogle Scholar
  • 51 Benhamou Y, Di M V, Bochet M. et al . Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.  Hepatology . 2001;  34 283-287
    CrossrefPubMedGoogle Scholar
  • 52 John M, Flexman J, French M AH. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?.  AIDS . 1998;  12 2289-2293
    CrossrefPubMedGoogle Scholar
  • 53 Gonzalez D R, Nunez M, Jimenez-Nacher I, Soriano V. Liver toxicity caused by nevirapine.  AIDS . 2002;  16 290-291
    CrossrefPubMedGoogle Scholar
  • 54 Poles M A, Dieterich D T, Schwarz E D. et al . Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV).  J Acquir Immune Defic Syndr Hum Retrovirol . 1996;  11 170-177
    PubMedGoogle Scholar
  • 55 Fagot J P, Mockenhaupt M, Bouwes-Bavinck J N. et al . Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.  AIDS . 2001;  15 1843-1848
    CrossrefPubMedGoogle Scholar
  • 56 Kessler H A, Johnson J, Follansbee S. et al . Abacavir expanded access program for adult patients infected with human immunodeficiency virus type 1.  Clin Infect Dis . 2002;  34 535-542
    CrossrefPubMedGoogle Scholar
  • 57 Frissen P H, de Vries J, Weigel H M, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.  AIDS . 2001;  15 289
    CrossrefPubMedGoogle Scholar
  • 58 Brinkman K, Smeitink J A, Romijn J A, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.  Lancet . 1999;  354 1112-1115
    CrossrefPubMedGoogle Scholar
  • 59 Gerard Y, Maulin L, Yazdanpanah Y. et al . Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy.  AIDS . 2000;  14 2723-2730
    PubMedGoogle Scholar
  • 60 Fortgang I S, Belitsos P C, Chaisson R E, Moore R D. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy.  Am J Gastroenterol . 1995;  90 1433-1436
    PubMedGoogle Scholar
  • 61 Miller K D, Cameron M, Wood L V, Dalakas M C, Kovacs J A. Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases.  Ann Intern Med . 2000;  133 192-196
    PubMedGoogle Scholar
  • 62 Torre D, Tambini R, Cadario F. et al . Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy.  Clin Infect Dis . 2001;  33 1579-1585
    CrossrefPubMedGoogle Scholar